scholarly journals Cigarette Smoker

2020 ◽  
Author(s):  
Keyword(s):  
1982 ◽  
Vol 7 (1) ◽  
pp. 83-86 ◽  
Author(s):  
Brett Silverstein ◽  
Eileen Kelly ◽  
Jane Swan ◽  
Lynn T. Kozlowski

2018 ◽  
Vol 13 (1) ◽  
pp. 8-12 ◽  
Author(s):  
Mehboba Ferdous ◽  
Sultana Ferdousi

Background: Cigarette smoking is associated with various forms of acute cardiac events such as myocardial infarction and ventricular fibrillation etc.Objective: To observe immediate impact of cigarette smoking on power spectral measures of heart rate variability (HRV) in current apparently healthy male regular cigarette smokers.Methods: This study was carried out on 120 apparently healthy male current regular cigarette smoker aged 20-55 years. To watch the intense impacts, data were recorded 5 and 30 min after completing a full stick of cigarette. Power spectral measures of HRV were recorded by a RMS digital polyrite D. Statistical analysis was done by paired sample t test.Results: LF power, LF nu & LF/HF ratio were significantly increased and HF power & HF nu were significantly decreased from their corresponding baseline value just 5 minutes after smoking and returned close to their baseline value after 30 minutes of smoking.Conclusion: The result of the study concludes that acceleration of sympathetic activity with simultaneous withdrawn of cardiovascular vagal adjustment happens quickly in the wake of smoking a cigarette.J Bangladesh Soc Physiol. 2018, June; 13(1): 8-12


2013 ◽  
Vol 1 (2) ◽  
pp. 80-83
Author(s):  
TM Ibrahim ◽  
MN Letchumanan

INTRODUCTION: Although hematogenous acute epididymo-orchitis complicating Gram negative bacteremia, tuberculosis and brucellosis have been reported in medical literature, there is paucity of report on acute epididymo-orchitis complicating Streptococcus pneumoniae bacteremia. CASE REPORT: We report the case of hematogenous acute epididymo-orchitis from S. pneumoniae bacteremia in an adult chronic cigarette smoker and alcoholic with community acquired pneumonia. CONCLUSION: We recommend that acute epididymo-orchitis should be remember as a sequel of S. pneumoniae bacteremia especially in adult males with immune suppression DOI: http://dx.doi.org/10.3126/ijim.v1i2.7411 Int J Infect Microbiol 2012;1(1):80-83


2019 ◽  
Vol 5 (1) ◽  
pp. 50-64 ◽  
Author(s):  
Eric K. Soule ◽  
Michael Chaiton ◽  
Bo Zhang ◽  
Marzena M. Hiler ◽  
Robert Schwartz ◽  
...  

PEDIATRICS ◽  
1991 ◽  
Vol 88 (2) ◽  
pp. 395-396
Author(s):  

In recent years, the development of a dangerous fad in which young people use clove cigarettes as an alternative to conventional cigarettes has occurred in several areas of the United States and Canada. Many users have the mistaken belief that clove cigarettes are an herbal, "natural," nontobacco alternative. Others are attracted to their use because of the association of clove cigarettes with the image of surfing, New Wave music, and the search for "exotic" and unusual experiences. More than 170 million clove cigarettes were sold at the height of their popularity in 1984, and sales were still averaging more than 40 million per year in 1985, 1986, and 1987.1(p3) This is even more remarkable when one considers that a significant portion of the consumers are under the legal age of purchase and that these sales have been achieved without the assistance of overt advertising. Indeed, a recent report of California youth in the 10th grade showed that 23% had tried clove cigarettes at least once. Furthermore, one third of those, approximately 8.5%, had used them at least once per month.2 Clove cigarettes are imported from Southeast Asia, principally from Indonesia, and are composed of approximately one third shredded cloves and two thirds tobacco. The type of tobacco in a clove cigarette delivers approximately twice as much tars, nicotine, and carbon monoxide as does tobacco in ordinary American cigarettes.1(pvi) In addition, substantial amounts of eugenol, an anesthetic agent, are found in cloves and in the smoke of clove cigarettes. The typical clove cigarette smoker inhales approximately 7 mg of eugenol per clove cigarette.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4804-4804
Author(s):  
Ruchika Goel ◽  
Kathryn Hassell ◽  
Oswaldo Castro ◽  
Robyn J. Barst ◽  
Erika Berman Rosenzweig ◽  
...  

Abstract Abstract 4804 Introduction: Smoking is known to promote vascular inflammation, in-vitro platelet aggregation and expression of endothelial adhesion molecules, processes that contribute to vasculopathy. Inflammation, abnormal platelet activation with thrombus formation and endothelial cell activation also play a role in vaso-occlusion in sickle cell disease (SCD). These overlapping pathobiological mechanisms suggest the possibility of a relationship between smoking and SCD vaso-occlusive pain. While small single center studies have suggested a link between environmental smoke exposure and hospitalization rate for acute chest syndrome and SCD pain (West et al 2003, Cohen et al 2010) there is a paucity of data derived from large multicenter studies about the interplay between smoking and pain phenotype in SCD. Aims: To determine the relationship between patient self reported chronic pain and history of current or former cigarette smoking in the SCD subjects screened in the walk-PHaSST study. Methods: Walk-PHaSST was a multi-center, placebo-controlled, double-blind 16-week trial designed to evaluate the safety and efficacy of sildenafil in patients with tricuspid regurgitant velocity [TRV] ≥2.7m/s and decreased exercise capacity as assessed by the six-minute walk distance (6MWD). We analyzed the data from all subjects screened for the walk-PHaSST trial. In the screening trial, subjects were evaluated by medical history, physical examination, laboratory screening, echocardiography and 6MWD testing. Univariate and stepwise multivariable logistic regression was used for this analysis. P value of <0.05 was considered statistically significant. Results: Of the 720 patients screened, medical history on pain and smoking was obtained in a total of 673 subjects. Of these, 483/673 subjects (72%) had HbSS disease and 137 (20.4%) had HbSC disease. Mean age was 36.6 years (median 36.1 years). A total of 104 (15.5%) were current smokers and 114 (17.4%) reported having smoked in the past and 451 (67.1%) subjects reported no history of any life-time or current smoking. Subjects had smoked for a mean of 11.5 years (median 9 years, range 1–42 years). The mean pack years of smoking were 8.8 (median 5 years, range <1- 60 pack years). In a multivariable logistic regression model, being a ‘current’ cigarette smoker was associated with an increased odds ratio (OR 3.0, 95% CI 1.8–4.9) (See Table 1) of reporting chronic SCD pain as compared to no smoking history when adjusted for 1) self reported acute pain, 2) age, 3) gender, 4) hematocrit 4) marijuana use, 5) SCD genotype and 6) current hydroxyurea treatment. Additionally, in the multivariable model, being a ‘former’ cigarette smoker was associated with a smaller effect size (OR 2.2, 95% CI 1.4–3.5) of reporting chronic SCD pain as compared with no smoking history when adjusted for the above listed variables. On examining by SCD genotypes, the effect size was similar for HbSS genotype (OR 2.79, 95% CI: 1.54–5.0) while the effect size was significantly higher for HbSC genotype (OR 5.6, 95% CI: 1.7–19.0). The increase in self reported pain with number of pack years adjusted for age was not statistically significant although an increase in reported pain was observed with increase in the number of pack years (See Figure 1). Conclusions: These data suggest that being a current or former smoker is independently associated with ‘self reported chronic SCD pain’ after adjusting for potential confounding variables including age of the patient, gender, hematocrit, marijuana use and being on hydroxyurea treatment. However, it is unclear whether smoking might worsen pain, represent a stress relieving behavior by patients to chronic pain or even provide a beneficial adaptation to chronic pain mediated by nicotine, carbon monoxide, nitric oxide, or other substances known to be present in tobacco smoke. These data provide a rationale for further mechanistic studies of the relationship between smoking and chronic pain in patients with SCD. Disclosures: Hassell: Novartis: Research Funding. Barst: Pfizer: Consultancy, Research Funding. Rosenzweig: Pfizer: Research Funding. Badesch: Pfizer: Honoraria, Research Funding.


2018 ◽  
Vol 19 (4) ◽  
pp. 364-370 ◽  
Author(s):  
Evelyn Vingilis ◽  
Linda L. Pederson ◽  
Jane Seeley ◽  
Anca R. Ialomiteanu ◽  
Christine M. Wickens ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document